Dova didn’t have to pay much when it bagged the rights to Doptelet (avatrombopag) from Eisai — laying out only $5 million for the castoff. And now that the FDA has come through with a marketing approval for a set of chronic liver disease patients suffering from low blood platelet counts, it’s not passing on any of the savings.